Esperion Therapeutics, Inc.
ESPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.03 | 0.02 | -0.01 |
| FCF Yield | -5.82% | -43.95% | -42.26% | -182.55% |
| EV / EBITDA | 113.39 | -5.11 | -3.12 | -0.88 |
| Quality | ||||
| ROIC | 26.87% | -180.99% | -122.31% | -83.70% |
| Gross Margin | 79.36% | 62.81% | 64.27% | 81.88% |
| Cash Conversion Ratio | 0.46 | 0.65 | 0.75 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 63.90% | 14.04% | -30.78% | -19.14% |
| Free Cash Flow Growth | 82.31% | 22.50% | 33.73% | -167.70% |
| Safety | ||||
| Net Debt / EBITDA | 58.98 | -3.06 | -0.77 | -0.23 |
| Interest Coverage | 0.92 | -2.64 | -3.16 | -4.89 |
| Efficiency | ||||
| Inventory Turnover | 0.73 | 0.66 | 0.77 | 0.41 |
| Cash Conversion Cycle | 315.97 | 438.17 | 327.71 | 538.92 |